valsartan has been researched along with Nephritis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, J; Huang, D; Jing, L; Wu, M | 1 |
| Bader, M; Baltatu, OC; Campos, LA; Louie, P; Schumacher, C; Zaugg, CE | 1 |
| Abe, M; Baba, S; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Takashima, H; Yoshida, Y | 1 |
| Hartner, A; Hilgers, KF; Mann, JF; Porst, M; Veelken, R | 1 |
1 trial(s) available for valsartan and Nephritis
| Article | Year |
|---|---|
Aliskiren reduces home blood pressure and albuminuria in patients with hypertensive nephrosclerosis.
Topics: Adult; Aged; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Female; Fumarates; Humans; Hypertension; Hypertension, Renal; Male; Middle Aged; Nephritis; Nephrosclerosis; Tetrazoles; Valine; Valsartan | 2013 |
3 other study(ies) available for valsartan and Nephritis
| Article | Year |
|---|---|
Valsartan in Combination with Tripterygium Glycosides Protects against Chronic Nephritis via the Toll-Like Receptor 4 Pathway.
Topics: Cholesterol, LDL; Glycosides; Humans; Interleukin-1beta; Interleukin-8; Nephritis; Toll-Like Receptor 4; Tripterygium; Valsartan | 2022 |
Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Antihypertensive Agents; Diuresis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hematocrit; Humans; Hypertension, Renal; Kidney; Male; Nephritis; Pyridines; Pyrimidines; Rats; Rats, Transgenic; Renin; Tetrazoles; Valine; Valsartan | 2014 |
Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Malignant; Hypertension, Renovascular; Immunohistochemistry; Kidney; Macrophages; Male; Nephritis; Organ Size; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Survival Rate; Tetrazoles; Valine; Valsartan | 2001 |